Methods in Pharmacoepidemiology / Study Design

(C-165) A Comparison of Concept Completeness in Single-Network and Multi-Site Approaches to Real-World Data Collection

(C-162) A Fitness-for-use Assessment of Real-World Data Sources and Data Linkage to inform a Post-Authorization Safety Study - A Formalized Feasibility Study

(C-171) Aligning Data Types with Research Needs: Insights from ISPE 2024 Oral Presentations by the IDSWG RWE sub-Team

(C-151) An algorithm for identifying observable medication time among US nursing home residents

(C-179) An Evaluation Strategy to Assess Patient Engagement Quality, Impact, and Outcomes

(C-148) Beyond Comparison: Target Trial Emulation (TTE) Principles Strengthen Observational Single-Arm (SA) Effectiveness Studies

(B-231) Comparison of prevalent new-user and sequential trial designs for studying the real-world effects of treatment discontinuation in cystic fibrosis

(C-159) Description of chronic graft versus host disease using an innovative Artificial Intelligence Natural language processing on electronic medical records from 8 centers in France

(C-176) Development and Verification of Robust Comprehensive Code Lists to Ensure Consistency Across Global Real-World Evidence Studies

(C-147) Does Health Plan Enrollment Data Support Long-term Follow-up of Patients with Chronic Disease? Assessment of the Healthcare Integrated Research Database (HIRD®)

(C-172) Effects of Biological Medication Exposure in Pregnancy and Neonatal Outcomes in Women with Autoimmune Diseases

(C-146) Evaluating Cenobamate among patients with Focal-Onset Seizures: defining a claims-based approach for treatment regimen and outcomes

(C-164) Exploring Index Event and Channeling Biases in the Evaluation of the Impact of Prior PARP Inhibitor (PARPi) Exposure on the Efficacy of Subsequent Platinum-Based Therapy Among Patients (Pts) with Ovarian Cancer (OC)

(C-158) Feasibility of Supplementing Single-Arm Trials with External Control Arms – Evaluation of German Real-World Data

(C-173) Framework for Integrating Physician Stakeholder Feedback into Real-world Data Studies

(C-163) Harmonizing Standards: Recommendations for Mitigating Gaps in Real-World Evidence (RWE) Feasibility Guidance

(C-157) β-Blockers and Risk of Neuropsychiatric Disorders: A Systematic Review and Meta-analysis.

(C-152) Impact of design choices that deviate from a target trial emulation. An application to the estimation of the effect of anticholinergic properties of antidepressants on the incidence of dementia

(C-143) Impact of study design specifications on effect size heterogeneity of myocarditis risk following COVID-19 vaccination: A systematic review, meta-analysis and meta-regression

(C-178) Informing Sample Size for External Control Arm Studies: Simulation-based Strategies for Rare Diseases and Subpopulations

(C-154) Integrating Mixed Methods and Actigraphy to Advance Understanding of Adverse Events in Metastatic Breast Cancer: A Multi-Country Study

(C-149) Longitudinal, Regulatory-Grade Registry Data Can Be Used to Emulate a Target Trial: An Application on Evaluating Treatments for Plaque Psoriasis

(C-153) Mind the Gap: a literature review to assess definitions of treatment discontinuation in oncology studies

(C-175) Myelofibrosis Patients Treated with Momelotinib vs. Best Available Therapy: Evaluating the Use of External Comparator Patients from the Optum Electronic Health Records Database.

(C-145) No Claim Left Behind: Viability of Assessing Early Real-World Vaccine Effectiveness in Open and Closed Administrative Healthcare Claims

(C-156) Nuances of Risk Window Selection for Evaluation of Acute Adverse Events

(C-177) Power vs Precision When Estimating Risk Differences Using Observational Data? A Case Study from TARGET-IBD

(C-144) Prevalent New User Design: Outcome Heterogeneity Based on Different Lengths of Time-Based Exposure Sets

(C-170) Quantifying the Effect of Treatment Switch: An Illustration with the Prevalent New User Design

(C-150) Review of Post-Authorization Safety Studies Submitted to the HMA-EMA Catalogue of RWD Studies Evaluating Cancer as an Outcome

(C-169) Revisiting Representativeness

(C-166) Safety of Transient Oral Corticosteroids Use in Mild-to-Moderate Asthma for Exacerbation Management: Methodological Review and Beyond

(C-161) Self-controlled Methodology and Test Negative Design to Evaluate Waning Effectiveness of COVID-19 and Influenza Vaccination in the Veterans Health Administration

(C-168) The Big Four: An Enhanced Framework for Drawing Causal Inferences from Observational Data

(C-167) Toward exposure-wide and outcome-wide pharmacoepidemiology for generating high-quality real-world evidence

(C-155) Transforming a Large-Scale Prostate Cancer Outcomes Dataset to the OMOP Common Data Model—Experiences with a Regional Health Record Database in China

(C-160) Using the Potential Outcomes Model to Inform the Design and Interpretation of Causal Studies of the Effectiveness and Safety of Healthcare Interventions: An Interdisciplinary Perspective

(C-174) Validating Early-stage Cancer Clinical Outcomes for Melanoma and Breast Cancer with Real World Data